Search and volunteer to participate in these available studies at UB. Your participation in research doesn't just benefit you, it helps advance healthcare for our entire community.
This study enrolls adults with Congenital Adrenal Hyperplasia. The purpose of this study is to see if an investigational drug called tildacerfont is safe and effective in reducing the level of certain hormones in your body. Read More
Eligibility:
Adults ages 18-55.
Has a documented historical diagnosis of classic Congenital Adrenal Hyperplasia (CAH)
This study enrolls people who have been diagnosed with a blood clot blocking an artery in their brain (stroke). The blocked artery is opened by removing the blood clot using a small catheter (thin tube) device that is inserted into an artery through your arm or leg that leads to your brain. The purpose of this study is to find out if this specific new investigational catheter (ZOOM) leads to improved outcomes at 90 days. Read More
Eligibility:
Adults ages 18+
Diagnosed with a stroke
Nonpregnant females
This study enrolls adults with nonalcoholic steatohepatitis (NASH). The purpose of this study is to learn about how much a medication called tirzepatide can help people with this condition. Read More
Eligibility:
Adults ages 18-80.
Overweight or obese.
Diagnosis of NASH by liver biopsy in the past 6 months.
Have fibrosis stage 2 or 3.
This study enrolls people who have been diagnosed with Tricuspid Regurgitation (TR). The purpose of this study is to look at the safety and effectiveness of this new investigational device compared to the standard medical treatment. Read More
Eligibility:
Adults ages 18+
Diagnosed with Tricuspid Regurgitation/Insufficiency
This is a 26-week open-label study to evaluate the safety and effectiveness of the study drug in the treatment of pediatric participants with schizophrenia or bipolar I disorder. Read More
Eligibility:
Males and females ages 13 to 18 with schizophrenia or 10 to 18 years of age with bipolar I disorder may be eligible for the study.
This study enrolls children and young adults with congenital anomalies of the kidney and urinary tract (CAKUT). The purpose of the study is to learn which gene mutation(s) may be responsible for this condition and to eventually find a gene therapy to treat this condition. Read More
Eligibility:
Children and young adults ages 0-21 years old with CAKUT (congenital anomalies of the kidney and urinary tract) seen at Oshei Children's Hospital
Patient's family member without CAKUT.
The purpose of this study is to develop a device to help people after they have had a stroke. This study looks at how the wrist moves when a person does everyday activities. Read More
Eligibility:
-Adults ages 18-65.
-Healthy and fit to perform active daily living tasks.
This study enrolls people who have had a brain aneurysm who will be treated with endovascular coil embolization. This procedure blocks blood flow to the bulging blood vessel in the brain. The purpose of this study is to learn how well SMART COIL System works for this type of procedure in everyday practice. The system is cleared by the FDA. Read More
Eligibility:
Adults ages 18+.
Will be having embolization of intracranial aneurysms procedure.
This study enrolls adults who work in a pharmacy that is part of the Community Pharmacy Enhanced Services Network (CPESN). The purpose of this study is to learn about if it would be feasible to make a Community Heath Worker (CHW) program embedded within a pharmacy practice. Read More
Eligibility:
Adults ages 18+.
Staff member in a pharmacy that is part of the Community Pharmacy Enhanced Services Network (CPESN) in New York and Missouri. Some of these pharmacies are implementing community health worker programs focused on patients with chronic health issues.
People eligible to participate in this study will be directly contacted by the study staff.
This study enrolls people who have have had a kidney transplant in the past year. The purpose of this study is to learn about outcomes in kidney Read More
Eligibility:
Adults ages 18+.
Recipient of a kidney transplant.
At least 1 year post-transplant (+/- 2 months).
Selected by provider to undergo TruGraf® testing as part of post-transplant care.